Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (201-210 of 264) with videos related to

Pageof 27
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experienceMarco Colleoni, David Zahrieh, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.
Cancer|December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trialJose P Leone, Bernard F Cole, Meredith M Regan, et al.
Breast Cancer Research and Treatment|May 9, 2019
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trialCarsten Denkert, Jan Budczies, Meredith M Regan, et al.
The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.
Ecancermedicalscience|September 18, 2014
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, MilanGauthier Bouche, Nicolas André, Shripad Banavali, et al.
Annals of Surgical Oncology|July 26, 2019
Update on the Feasibility and Progress on Robotic Breast SurgeryAntonio Toesca, Alessandra Invento, Giulia Massari, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 30, 2021
Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapyMaria Cristina Leonardi, Camilla Arrobbio, Sara Gandini, et al.
Breast Care (Basel, Switzerland)|June 30, 2021
Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, ItalyMaria Cristina Leonardi, Emilia Montagna, Viviana Enrica Galimberti, et al.
Pageof 27

Showing results (201-210 of 264) with videos related to

Sort By:
Pageof 27
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experienceMarco Colleoni, David Zahrieh, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.
Cancer|December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trialJose P Leone, Bernard F Cole, Meredith M Regan, et al.
Breast Cancer Research and Treatment|May 9, 2019
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trialCarsten Denkert, Jan Budczies, Meredith M Regan, et al.
The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.
Ecancermedicalscience|September 18, 2014
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, MilanGauthier Bouche, Nicolas André, Shripad Banavali, et al.
Annals of Surgical Oncology|July 26, 2019
Update on the Feasibility and Progress on Robotic Breast SurgeryAntonio Toesca, Alessandra Invento, Giulia Massari, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 30, 2021
Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapyMaria Cristina Leonardi, Camilla Arrobbio, Sara Gandini, et al.
Breast Care (Basel, Switzerland)|June 30, 2021
Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, ItalyMaria Cristina Leonardi, Emilia Montagna, Viviana Enrica Galimberti, et al.
Pageof 27